Early research (Phase 1)Study completedNCT03298516
What this trial is testing
DCLL9718S in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or DCLL9718S in Combination With Azacitidine in Participants With Previously Untreated AML Unsuitable for Intensive Induction Chemotherapy
Who this might be right for
Leukemia, Myeloid, Acute
Genentech, Inc. 19